Table 2.
Antithrombotic management in NSTEMI patients
| Time post‐discharge (months) | |||||
|---|---|---|---|---|---|
| Discharge | 6 | 12 | 18 | 24 | |
| n = 2549 | n = 2412 | n = 2312 | n = 2197 | n = 2032 | |
| AP therapy, n (%) | |||||
| DAPTa | 2315 (90.8) | 2051 (85.0) | 1832 (79.1) | 1429 (65.0) | 1219 (60.0) |
| Aspirin + P2Y12ib | 2247 (88.2) | 2009 (83.3) | 1797 (77.7) | 1399 (63.7) | 1192 (58.7) |
| Other DAPT | 68 (2.7) | 42 (1.7) | 35 (1.5) | 30 (1.4) | 27 (1.3) |
| SAPT | 230 (9.0) | 328 (13.6) | 426 (18.4) | 680 (31.0) | 710 (34.9) |
| Aspirin only | 111 (4.4) | 198 (8.2) | 286 (12.4) | 538 (24.5) | 576 (28.4) |
| P2Y12ib | 118 (4.6) | 128 (5.3) | 137 (5.9) | 139 (6.3) | 130 (6.4) |
| Other single AP | 1 (0.04) | 2 (0.1) | 3 (0.1) | 3 (0.1) | 4 (0.2) |
| No AP therapy | 4 (0.2) | 33 (1.4) | 54 (2.3) | 88 (4.0) | 103 (5.1) |
| AC therapy, n (%) | 29 (1.1) | 23 (1.0) | 22 (1.0) | 22 (1.0) | 20 (1.0) |
| AC + AP | 26 (1.0) | 21 (0.9) | 20 (0.9) | 19 (0.9) | 18 (0.9) |
| AC only | 3 (0.1) | 2 (0.1) | 2 (0.1) | 3 (0.1) | 2 (0.1) |
| Death and loss to follow‐up, n | |||||
| Death (cumulative) | — | 71 | 127 | 162 | 191 |
| Lost to follow‐up (cumulative) | — | 66 | 110 | 190 | 326 |
| AP therapy in patients discharged on DAPTa (n = 2315), n (%) | — | n = 2192 | n = 2108 | n = 2012 | n = 1866 |
| DAPT | — | 2051 (93.6) | 1831 (86.9) | 1427 (70.9) | 1217 (65.2) |
| SAPT | — | 117 (5.3) | 232 (11.0) | 506 (25.2) | 557 (29.9) |
| No AP therapy | — | 24 (1.1) | 45 (2.1) | 79 (3.9) | 92 (4.9) |
Abbreviations: AC, anticoagulant; AP, antiplatelet; DAPT, dual antiplatelet therapy; P2Y12i, P2Y12 receptor inhibitor; SAPT, single antiplatelet therapy.
a
Includes all patients discharged on two or more antiplatelets (ie, including triple antiplatelet therapy) from the index hospitalization. DAPT during follow‐up is defined as the use of two or more antiplatelets not accounting for interruptions.
b
99% clopidogrel.